Rapid Therapy Guidance™ Test
Advanced/Metastatic Cancers (Pan-Cancer)
Commercial (Early Access)Active
Key Facts
Indication
Advanced/Metastatic Cancers (Pan-Cancer)
Phase
Commercial (Early Access)
Status
Active
Company
About Travera
Travera is a private, early-stage diagnostics company founded in 2018 and based in Cambridge, MA. It has developed a novel functional precision oncology platform that measures changes in cancer cell mass (Mass Response Testing, MRT) in response to drug exposure, enabling a rapid 2-day turnaround for therapy guidance. The company is currently generating early clinical evidence through studies with major U.S. cancer centers and is in a pre-revenue, early-access commercial phase. Its core value proposition is speed and broad applicability, offering an alternative or complement to genomic-based testing.
View full company profile